Genocea raises $23M in financing led by GSK venture arm
Genocea Biosciences, a US vaccine discovery and development company, has raised $23.0 million in a series A financing led by SR One, the corporate venture arm of UK drug giant GlaxoSmithKline. New investors Auriga Partners, Cycad Group and Alexandria Real Estate Equities also participated in the financing and were joined by returning founding investors Lux Capital Management, Polaris Venture Partners and Morningside Ventures.
"Novel prophylactic and therapeutic vaccines are one of the most important unmet needs in global health," said SR-One president Russell Greig. "Genocea has a one-of-a-kind technology, strong business model, and outstanding team for developing vaccines against many of the world's remaining disease targets. SR-One is proud to be part of such a great syndicate and opportunity," he added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze